Skip to main content
logo
LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
4.770
-0.020 (-0.42%)
At close: Aug 18, 2026, 4:00 PM EDT
4.850
+0.080 (1.68%)
After-hours: Aug 18, 2026, 7:36 PM EDT

LENZ Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
21.4819.09--15-
Revenue Growth
329.50%-----
Cost of Revenue
1.770.42----
Gross Profit
19.718.67--15-
Selling, General & Admin
151.5791.1428.8112.934.362.47
Research & Development
3.7918.6729.859.521.134.22
Operating Expenses
155.36109.8158.6172.4325.486.69
Operating Income
-135.66-91.14-58.61-72.43-10.48-6.69
Interest & Investment Income
10.19.768.552.190-
Other Non Operating Income (Expenses)
-0.24-0.240.290.090.02-0.87
Pretax Income
-126-81.63-49.77-70.15-10.46-7.56
Income Tax Expense
0.010.50-0.180.35-
Net Income
-126-82.13-49.77-69.97-10.81-7.56
Net Income to Common
-126-82.13-49.77-69.97-10.81-7.56
Net Income Growth
------
Shares Outstanding (Basic)
312921299
Shares Outstanding (Diluted)
312921299
Shares Change
10.84%35.39%986.27%-79.28%1.05%-
EPS (Basic)
-4.12-2.85-2.34-35.71-1.14-0.81
EPS (Diluted)
-4.12-2.85-2.34-35.71-1.14-0.81
EPS Growth
------
Free Cash Flow
-114.42-70-59.86-60.41-4.13-5.4
Free Cash Flow Per Share
-3.74-2.43-2.81-30.84-0.44-0.58
Gross Margin
91.74%97.81%--100.00%-
Operating Margin
-631.70%-477.46%---69.89%-
Profit Margin
-586.74%-430.25%---72.07%-
Free Cash Flow Margin
-532.80%-366.71%---27.52%-
EBITDA
-135.2-90.85-58.55-72.41-10.48-6.69
EBITDA Margin
-----69.83%-
D&A For EBITDA
0.450.290.060.020.010
EBIT
-135.66-91.14-58.61-72.43-10.48-6.69
EBIT Margin
-----69.89%-
Revenue as Reported
21.4819.09--15-
Advertising Expenses
-8----
SEC Filings: 10-K · 10-Q